



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 471/10 // A61K 31/435 (C07D 471/10, 221/00, 209/00)	A1	(11) International Publication Number: WO 92/06975 (43) International Publication Date: 30 April 1992 (30.04.92)
(21) International Application Number: PCT/US91/07473 (22) International Filing Date: 10 October 1991 (10.10.91) (30) Priority data: 596,266 12 October 1990 (12.10.90) US (71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; 685 Third Avenue, New York, NY 10017 (US). (72) Inventor: MALAMAS, Michael, Sotirios ; 2443 Oleander Circle, Jamison, PA 18929 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corporation, 685 Third Avenue, New York, NY 10017 (US) et al.		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), SU ⁺ . Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 1'-AMINOSPIRO[ISOQUINOLINE-4(1H),3'-PYRROLIDINE]-1,2',3,5'(2H)-TETRONES AND ANALOGS THEREOF USEFUL AS ALDOSE REDUCTASE INHIBITORS (57) Abstract <p>This invention relates to 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for the prevention or treatment of diabetes mellitus associated complications.</p>		

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU ⁺	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TC	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

- 1 -

**1'-AMINOSPIRO[ISOQUINOLINE-4(1H),3'-PYRROLIDINE]-
1,2',3,5'(2H)-TETRONES AND ANALOGS THEREOF
USEFUL AS ALDOSE REDUCTASE INHIBITORS**

Background of the Invention

5 This invention relates to 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-
1,2',3,5'(2H)-tetrones and their pharmaceutically acceptable salts thereof, to processes
for their preparation, to methods for using the compounds, and to pharmaceutical
preparations thereof. The compounds have pharmaceutical properties which render
them beneficial for the prevention or treatment of complications associated with diabetes
10 mellitus.

The use of insulin and/or oral hypoglycemic agents in the treatment of diabetes
mellitus has prolonged the life of many of these patients. However, their use has not
had a demonstrable impact on the development of diabetic complications such as
neuropathy, nephropathy, retinopathy, cataracts and vascular disease which accompany
15 the underlying metabolic disorder. There is little question that chronic hyperglycemia
plays a major role in the genesis of these complications, and that complete
normalization of blood glucose would likely prevent most if not all complications. For
a number of reasons, though, chronic normalization of blood glucose has not been
achieved with the currently available therapies.


20 The long-term complications of diabetes develop in tissues where glucose
uptake is independent of insulin. In these tissues, which include the lens, retina,
kidney and peripheral nerves, the systemic hyperglycemia of diabetes is rapidly
transposed into high tissular concentrations of glucose. In all of these tissues this
excess glucose is rapidly metabolized by the sorbitol pathway. The intense diabetes-
25 induced flux of glucose through this pathway appears to initiate a cascade of
biochemical alterations which slowly progress to cell dysfunction and structural
damage. Aldose reductase, the key enzyme in the sorbitol pathway, reduces glucose to
sorbitol at the expense of the cofactor NADPH. In animal models of diabetes,
compounds which inhibit aldose reductase have been shown to prevent the
30 biochemical, functional and morphological changes induced by hyperglycemia. Early
studies by J. H. Kinoshita and collaborators implicated aldose reductase in the etiology
of diabetic cataracts. More recent studies have provided compelling evidence that
aldose reductase also plays a significant role in the initiation of diabetic nephropathy,

- 2 -

retinopathy and neuropathy (cf McCaleb et al, J. Diab. Comp., 2, 16, 1989; Robison et al, Invest. Ophthalmol. Vis. Sci., 30,, 2285, 1989; Notvest and Inserra, Diabetes, 36, 500, 1987.

Prior Art

- 5 The closest prior art is Malamas U.S. Patent 4,927,831, May 22, 1990, which discloses the spiro-isoquinoline-pyrrolidine tetrones of formula




(R¹ is hydrogen or fluorine)

useful as aldose reductase inhibitors for treating complications of diabetes and galactosemia.

10

Summary of Invention

The 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones of the present invention are represented by formula (I):



wherein:


- 15 R¹ and R² are independently hydrogen, alkyl containing 1 to 6 carbon atoms, halogen, lower alkoxy containing 1 to 6 carbon atoms, trifluoromethyl, nitro, aryl or aryl (lower alkyl) oxy wherein aryl contains 6 to 10 carbon atoms and lower alkyl contains 1 to 6 carbon atoms;

- 3 -

R³ is lower alkyl containing 1 to 6 carbon atoms, aryl, aryl (lower alkyl) or dihalogen substituted aryl (lower alkyl) wherein aryl contains 6 to 10 carbon atoms and lower alkyl contains 1 to 6 carbon atoms;

5 R⁴ and R⁵ are independently hydrogen, alkyl containing 1 to 6 carbon atoms, aryl or aryl (lower alkyl) wherein aryl contains 6 to 10 carbon atoms and lower alkyl contains 1 to 6 carbon atoms, alkanoyl of 2 to 5 carbon atoms, carboalkoxy, alkylsulfoxy, arylsulfoxy, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl or R⁴ and R⁵ are joined to form a heterocyclic ring of 5 to 7 ring atoms including the nitrogen atom to which they are joined, and pharmaceutically acceptable salts thereof
10 when R⁴ and R⁵ are hydrogen, alkyl or aryl.

A more preferred group of compounds of the present invention is represented by formula (II):



15 wherein R¹ and R² are hydrogen or halogen, R³ is a dihalogen substituted benzyl, R⁴ and R⁵ are hydrogen, acyl, carboalkoxy or trifluoromethanesulfonyl.

The most preferred compounds of the present invention are set forth below:

1'-amino-2-[(4-bromo-2-fluorophenyl)methyl]spiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone;

20 1'-amino-2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H), 3'-pyrrolidine]-1,2',3,5'(2H)-tetrone;

N-[2-[(4-bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]iminodicarbonic acid dimethyl ester;

- 4 -

N-[2-[(4-bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]acetamide; and

N-[2-[(4-bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]-1,1,1-trifluoromethanesulfonamide.

5 The compounds of formula (I) all possess at least one asymmetric carbon atom, namely the spiro carbon atom at position 3' of the pyrrolidine ring. The compounds of formula (I) therefore exist, and may be isolated, in two or more stereoisomeric forms. This invention encompasses the compounds of formula (I) in racemic form or in any optically active form.

10 The 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone can be prepared by the processes described hereinafter.

 A method is provided for preventing or relieving diabetes mellitus associated complications in a diabetic mammal by administering to said mammal a prophylactic or alleviating amount of the compounds of formula (I). Such complications include
15 neuropathy, nephropathy, retinopathy, keratopathy, diabetic uveitis, cataracts and limited joint mobility.

 The compounds of formula (I), when admixed with a pharmaceutically acceptable carrier, form a pharmaceutical composition which can be used according to the preceding method.

20 The 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone of this invention may be administered to mammals, for example, man, cattle, or rabbits, either alone or in dosage forms, i.e., capsules or tablets, combined with pharmacologically acceptable excipients.

 The compounds of this invention may be given orally. However, the method of
25 administering the present active ingredients of this invention is not to be construed as limited to a particular mode of administration. For example, the compounds may be administered topically directly to the eye in the form of drops of sterile, buffered ophthalmic solutions, preferably of pH 7.2-7.6. Also, they may be administered orally in solid form containing such excipients as starch, milk sugar, certain types of clay and
30 so forth. They may also be administered orally in the form of solutions or they may be injected parenterally. For parenteral administration, they may be used in the form of a

- 5 -

sterile solution, preferably of pH 7.2-7.6, containing a pharmaceutically acceptable buffer.

The dosage of the 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'-(2H)-tetrone will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less than the optimal dose of the compound. Thereafter, the dosage is increased by small increments until efficacy is obtained. In general, the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects. For topical administration, a 0.05-1.0% solution may be administered dropwise in the eye. The frequency of instillation varies with the subject under treatment from a drop every two or three days to once daily. For oral or parenteral administration a preferred level of dosage ranges from about 1.0 mg to about 10.0 mg per kilo of body weight per day, although aforementioned variations will occur. However, a dosage level that is in the range of from about 1.0 mg to about 10.0 mg per kilo of body weight per day is most satisfactory.

Unit dosage forms such as capsules, tablets, pills and the like may contain from about 5.0 mg to about 25.0 mg of the active ingredients of this invention with a pharmaceutical carrier. Thus, for oral administration, capsules can contain from between about 5.0 mg to about 25.0 mg of the active ingredients of this invention with or without a pharmaceutical diluent. Tablets, either effervescent or noneffervescent, can contain between about 5.0 to 25.0 mg of the active ingredients of this invention together with conventional pharmaceutical carriers. Thus tablets, which may be coated and either effervescent or noneffervescent, may be prepared according to the known art. Inert diluents or carriers, for example, magnesium carbonate or lactose, can be used together with conventional disintegrating agents for example, magnesium stearate.

The 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'-(2H)-tetrone also can be used in combination with insulin or oral hypoglycemic agents to produce a beneficial effect in the treatment of diabetes mellitus. In this instance, commercially available insulin preparations or oral hypoglycemic agents, exemplified by acetohexamide, chlorpropamide, tolazamide, tolbutamide and phenformin, are suitable. The compounds hereof can be administered sequentially or simultaneously with insulin or the oral hypoglycemic agent. Suitable methods of administration, compositions and doses of the insulin preparation or oral hypoglycemic agent are described in medical

- 6 -

textbooks; for instance, *Physicians' Desk Reference*, 42 ed., Medical Economics Co., Oradell, N.J., U.S.A., 1988.

The aldose reductase inhibiting property of the compounds of this invention and the utilization of the compounds in preventing, diminishing and alleviating diabetic complications are demonstrable in experiments using galactosemic rats, see Dvornik *et al.*, *Science*, 182, 1146 (1973). Such experiments are exemplified hereinbelow after the listing of the following general comments pertaining to these experiments:

(a) Four or more groups of six male rats, 50-70 g, Sprague-Dawley strain, were used. The first group, the control group, was fed a mixture of laboratory chow (rodent Laboratory Chow, Purina) and glucose at 20% (w/w %) concentration. An untreated galactosemic group was fed a similar diet in which galactose was substituted for glucose. The third group was fed a diet prepared by mixing a given amount of the test compound with the galactose containing diet. The concentration of galactose in the diet of the treated groups was the same as that for the untreated galactosemic group.


(b) After four days, the animals were killed by euthanization. Both the lens and sciatic nerve were removed, weighed and stored frozen for polyol determination.

(c) The polyol determination was performed by a modification of the procedure of M. Kraml and L. Cosyns, *Clin. Biochem.*, 2, 373 (1969). Only two minor reagent changes were made: (a) the rinsing mixture was an aqueous 5% (w/v) trichloroacetic acid solution and (b) the stock solution was prepared by dissolving 25 mg of dulcitol in 100 mL of an aqueous trichloroacetic acid solution. [N.B.: For each experiment the average value found in the tissue from rats fed the glucose diet was subtracted from the individual values found in the corresponding tissue in galactose-fed rats to obtain the amount of polyol accumulated.] The aldose reductase inhibiting effects of the compounds of formula (I) were also tested by employing an *in vitro* testing procedure similar to that described by S. Hayman and J.H. Kinoshita, *J. Biol. Chem.*, 240, 877 (1965). In the present case the procedure of Hayman and Kinoshita was modified in that the final chromatography step was omitted in the preparation of the enzyme from bovine lens.

The following tabulated results show that the 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones of this invention show the property that they are active *in vivo* and diminish the accumulation of dulcitol in the lenses, sciatic nerves and diaphragm of rats fed galactose. The figures under L, N, and D represent the percentage decrease of dulcitol accumulation in the tissues of the lens, sciatic nerve, and diaphragm, respectively, for treated rats as compared to untreated rats.

- 7 -

ALDOSE REDUCTASE INHIBITORS



5

	R¹	R⁴	R⁵	% Inhibition <i>In Vitro</i> 10⁻⁵M	Dose mg/kg/day	% Lowering Galactitol Accumulation <i>In Vivo</i>		
						%(L)	%(N)	%(D)
10	H	H	H	5	56	82	72	97
	F	H	H	0	50.5	54	75	96
	H	H	COCH₃	20	57	25	73	90
15	H	H	SO₂CF₃	0	55	NS	NS	66
	H	CO₂CH₃	CO₂CH₃	0	55	NS	50	82

(NS = not significant)


- 8 -

This invention also provides processes for preparing the compounds of formula I or salts thereof. In particular the compounds of formula I may be prepared by one of the following:

a) acylating a compound of formula



wherein R^4 and R^5 are as defined above with a compound of formula



or an activated form thereof

10 wherein CO_2R^6 is an ester function, e.g. alkyl ester such as the methyl ester, and R^1 , R^2 and R^3 are as defined above to give a corresponding compound of formula I and if desired where possible isolating as a salt,

or

15 b) acylating a compound of formula I wherein one of R^4 and R^5 is hydrogen, the other is selected from hydrogen, lower alkyl, aryl or aryl(loweralkyl)- with an acylating agent (including sulfonylating and sulfinylating agents) containing the group



- 9 -

where R^8 is alkyl and R^9 is alkyl or aryl or, when n is 1, R^9 also represents trifluoromethyl, to give a corresponding compound of formula I wherein R^4 is hydrogen, alkyl, aryl or aryl(loweralkoxy) and R^5 is alkanoyl, carboalkoxy, alkylsulfoxy, arylsulfoxy, alkylsulfonyl, arylsulfonyl or trifluoromethylsulfonyl or R^4 and R^5 are both
5 alkoxy carbonyl, alkanoyl, alkylsulfoxy, arylsulfoxy, alkylsulfonyl, arylsulfonyl or trifluoromethylsulfonyl.

With regard to process a) the acylation may be carried out using the carboxylic acid of formula XIV and a coupling agent such as a carbodiimide e.g. dicyclohexylcarbodiimide. Alternatively the carboxylic acid group may be in activated
10 form e.g. as an acid halide such as the chloride or bromide, or an anhydride such as a mixed anhydride. Processes for preparing compounds of formula III are described in Publication No. GB 2224734 and EP Publication No. 365324


With regard to process b) examples of the acylating agent are acid halides and anhydrides e.g. compounds of formula R^8COhal , $(R^8CO)_2O$, $R^9S(O)_nhal$,
15 $(R^9SO_2)_2O$ and haloformates such as $Cl COOR^8$.

Multiple acylation may be effected using a stoichiometric excess of acylating agent and more vigorous acylating conditions.

Preferred routes to compounds of the invention are shown in the process below:-

- 10 -

The Process: The 1'-aminospiro[isochroman-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones of the present invention were prepared by the following reaction scheme:



wherein R^1 is halogen or hydrogen and R^3 is a disubstituted aralkyl.

- 11 -

Step a) Reacting either 2-bromobenzoic acid or 2-chlorobenzoic acid of formula (III) wherein R^1 is as defined above with dimethyl malonate and NaH in the presence of a catalytic amount of CuBr to produce the propanedioic acid dimethyl ester of formula (IV) wherein R^1 is as defined above.

5 The 2-bromobenzoic acids or 2-chlorobenzoic acids of formula (III) required for the present invention are commercially available compounds or can be prepared by known methods.

Step b) The propanedioic acid dimethyl ester of formula (IV) can be reacted with thionyl chloride under refluxing conditions to produce the corresponding acid chloride
10 which upon treatment with Et_3N in a conventional solvent which does not adversely influence the reaction, for example, tetrahydrofuran, can produce the compound of formula (V), wherein R^1 is as defined above.

Step c) The compound of formula (V), wherein R^1 is as defined above, is
15 reacted with R^3-NH_2 in the presence of Et_3N in a conventional solvent which does not adversely influence the reaction, for example, DMF, produces the compound of the formula (VI), wherein R^1 and R^3 are as defined above.

Step d) The compound of formula (VI), wherein R^1 and R^3 are as defined
20 above, is reacted with an inorganic base such as potassium carbonate in a conventional solvent which does not adversely influence the reaction, for example, N,N-dimethylformamide and subsequent addition of the tert-butyl bromoacetate produces the compound of formula (VII), wherein R^1 and R^3 are as defined above.

Step e) The compound of formula (VII), wherein R^1 and R^3 are as defined
25 above, can be reacted with an organic acid such as trifluoroacetic acid in a conventional solvent which does not adversely influence the reaction, for example, methylene chloride, to produce the compound of formula (VIII), wherein R^1 and R^3 are as defined above.

Step f) The compound of formula (VIII), wherein R^1 and R^3 are as defined
above, can be reacted with a coupling agent such as 1-(3-dimethylaminopropyl)-3-

- 12 -

ethylcarbodiimide (DCC)/1-hydroxybenzotriazole (HOBT) in a conventional solvent which does not adversely influence the reaction, for example, N,N-dimethylformamide, and subsequent addition of hydrazine and Et₃N, produces the compound of formula (IX), wherein R¹ and R³ are as defined above.

5 Step g) The compound of formula (IX), wherein R¹ and R³ are as defined above can be reacted with methyl chloroformate in the presence of Et₃N in a conventional solvent which does not adversely influence the reaction, for example, tetrahydrofuran, to produce the compound of formula (X), wherein R¹ and R³ are as defined above.

10 Step h) The compound of formula (IX), wherein R¹ and R³ are as defined above, can be reacted with acetic anhydride at 70°C, to produce the compound of formula (XI), wherein R¹ and R³ are as defined above.

15 Step i) The compound of formula (IX), wherein R¹ and R³ are as defined above, can be reacted with trifluoromethanesulfonic anhydride in the presence of Et₃N in a conventional solvent which does not adversely influence the reaction, for example, methylene chloride, to produce the compound of formula (XII), wherein R¹ and R³ are as defined above.

The following examples further illustrate this invention:

EXAMPLE 1

20 **1'-Amino-2-[(4-bromo-2-fluorophenyl)methyl]spiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone**

Step a) (2-Carboxyphenyl)propanedioic Acid Dimethyl Ester

25 To a rapidly stirred cold suspension (0°C) of 2-bromobenzoic acid (30.0 g, 149.32 mmol), cuprous bromide (2.14 g, 14.93 mmol) and dimethyl malonate (300 mL) was added NaH (80% in mineral oil, 10.75 g, 358.37 mmol) over a 30 minute period, while a stream of dry N₂ was passed over the mixture. After the addition of the NaH had been completed, the mixture was stirred for 10 minutes at room temperature and 30 minutes at 70°C (external oil bath temperature). At this point, the suspension had turned to a solid mass, which was dissolved in H₂O (1000 mL). The aqueous layer was extracted with diethyl ether (3 x 500 mL) and was acidified with HCl (2N).
30 The mixture was extracted with EtOAc and dried over MgSO₄. Evaporation gave an

- 13 -

off-white solid which was recrystallized from Et₂O/hexane (after cooling to -20°C) to give a white solid (34.2 g, 90.9%, m.p. 119-120°C).

¹H NMR (DMSO-d₆, 400 MHz): δ 3.67 [s, 6H, -CH(CO₂CH₃)₂], 5.72 [s, 1H, -CH(CO₂CH₃)₂], 7.3 (d, J = 7.76 Hz, 1H, Ar-H), 7.45 (dt, J = 7.66 Hz, 1.12 Hz, 1H, Ar-H), 7.6 (dt, J = 7.66 Hz, 1.45 Hz, 1H, Ar-H), 7.94 (dd, J = 7.8 Hz, 1.33 Hz, 1H, Ar-H), 13.2 (s, 1H, -CO₂H)

IR (KBr, cm⁻¹): 3300-2700 (CO₂H), 1750 (CO), 1730 (CO), 1680 (CO)

MS (m/e): 252 (M⁺), 220 (M⁺-CH₃OH), 188 (M⁺-2 x CH₃OH)

Anal. Calcd.: C, 57.14; H, 4.80

10 Found: C, 57.05; H, 4.78.

The following compounds were prepared in substantially the same manner as that of Example 1, Step a):

(2-Carboxy-6-fluorophenyl)propanedioic Acid Dimethyl Ester

¹H NMR (DMSO-d₆, 400 MHz): δ 3.68 [s, 6H, (-CO₂Me)₂], 5.79 [s, 1H, Ar-CH(CO₂Me)₂], 7.12 (dd, J = 10.06 Hz, 2.61 Hz, 1H, Ar-H), 7.33 (dt, J = 8.48 Hz, 2.64 Hz, 1H, Ar-H), 8.03 (dd, 8.77 Hz, 6.17 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 3400-2700 (CO₂H), 1730 (CO), 1680 (CO)

MS (m/e): 270 (M⁺), 238 (M⁺-CH₃OH), 210 (M⁺-CH₃OH, -CO), 151 (M⁺-CH₃OH, -CO, -CO₂CH₃)

20 Anal. Calcd.: C, 53.34; H, 4.10

Found: C, 53.36; H, 3.93

m.p. 121.5-123.0°C.

(2-Carboxy-6-chlorophenyl)propanedioic Acid Dimethyl Ester

¹H NMR (DMSO-d₆, 200 MHz): δ 3.69 [s, 6H, (-CO₂Me)₂], 5.78 [s, 1H, Ar-CH(CO₂Me)₂], 7.38 (d, J = 1.8 Hz, 1H, Ar-H), 7.58 (dd, J = 7.8 Hz, 1.8 Hz, 1H, Ar-H), 7.96 (d, J = 8.2 Hz, 1H, Ar-H), 13.5 (br s, 1H, -CO₂H)

IR (KBr, cm⁻¹): 3200-2700 (CO₂H), 1760 (CO), 1740 (CO), 1690 (CO)

MS (m/e): 286 (20 M⁺), 254 (64, M⁺-CH₃OH), 222 (60, M⁺-2 x CH₃OH)

Anal. Calcd.: C, 50.28; H, 3.87

30 Found: C, 50.40; H, 3.87

m.p. 125-127°C.

- 14 -

(2-Carboxy-6-bromophenyl)propanedioic Acid Dimethyl Ester

¹H NMR (DMSO-d₆, 400 MHz): δ 3.68 [s, 6H, -(CO₂CH₃)₂], 5.74 (s, 1H, Ar-CH-), 7.5 (d, J = 2.02 Hz, 1H, Ar-H), 7.70 (dd, J = 8.4 Hz, 1.98 Hz, 1H, Ar-H), 7.87 (d, J = 8.41 Hz, 1H, Ar-H)

5 IR (KBr, cm⁻¹): 3400-2300 (CO₂H), 1745 (CO), 1720 (CO), 1695 (CO)

MS (m/e): 330 (M⁺), 298 (M⁺-CH₃OH)

Anal. Calcd.: C, 43.53; H, 3.35

Found: C, 43.56; H, 3.23

m.p. 127-128°C.

10 **Step b) 3-Methoxy-1-oxo-1H-2-benzopyran-4-carboxylic Acid Methyl Ester**

A mixture of (2-carboxyphenyl)propanedioic acid dimethyl ester (10.0 g, 39.68 mmol) and SOCl₂ (100 g) was refluxed for 2 hours. The volatiles were removed *in vacuo* and the crude product (acid chloride) was dissolved in THF (200 mL).

15 Triethylamine (27.64 mL, 198.4 mmol) was added and the mixture was stirred for 30 minutes. The yellowish suspension was poured into HCl (1N, 1000 mL), extracted with EtOAc and the organic extracts were dried over MgSO₄. Evaporation and crystallization from acetone/ether/hexane (after cooling to -20°C) gave a white solid (87.6 g, 94.4%, m.p. 129-130°C).

20 ¹H NMR (DMSO-d₆, 400 MHz): δ 3.82, (s, 3H, -CO₂Me), 4.03 (s, 3H, -OMe), 7.42 (t, J = 7.26 Hz, 1H, Ar-H), 7.8 (t, J = 8.2 Hz, 1H, Ar-H), 7.9 (d, J = 8.3 Hz, 1H, Ar-H), 8.1 (d, J = 7.26 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 1740 (CO), 1685 (CO)

MS (m/e): 234 (15, M⁺), 206 (38.5, M⁺-CO), 203 (12, M⁺-OMe)

25 Anal. Calcd.: C, 61.59; H, 4.30

Found: C, 61.82; H, 4.29.

- 15 -

The following compounds were prepared in substantially the same manner as that of Example 1, Step b):

6-Fluoro-3-methoxy-1-oxo-1H-2-benzopyran-4-carboxylic Acid Methyl Ester

5 ^1H NMR (DMSO- d_6 , 400 MHz): δ 3.81 (s, 3H, $-\text{CO}_2\text{CH}_3$), 4.06 (s, 3H, $-\text{OCH}_3$ -), 7.27 (dt, $J = 8.3$ Hz, 1H, Ar-H), 7.8 (dd, $J = 11.83$ Hz, 2.49 Hz, 1H, Ar-H), 8.16 (dd, $J = 8.92$ Hz, 6.2 Hz, 1H, Ar-H)

IR (KBr, cm^{-1}): 1750 (CO), 1685 (CO)

MS (m/e): 252 (24, M^+), 224 (54, $\text{M}^+ - \text{CO}$)

10 Anal. Calcd.: C, 57.15; H, 3.60

Found: C, 57.19; H, 3.57

m.p. 142-143°C.

6-Chloro-3-methoxy-1-oxo-1H-2-benzopyran-4-carboxylic Acid Methyl Ester

15 ^1H NMR (DMSO- D_6 , 400 MHz): δ 3.81 (s, 3H, $-\text{CO}_2\text{CH}_3$), 4.05 (s, 3H, $-\text{OCH}_3$ -), 7.44 (dd, $J = 8.56$ Hz, 1.99 Hz, 1H, Ar-H), 8.06 (m, 2H, Ar-H)

IR (KBr, cm^{-1}): 1750 (CO), 1690 (CO)

MS (m/e): 268 (34, M^+), 240 (86, $\text{M}^+ - \text{CO}$)

Anal. Calcd.: C, 53.65; H, 3.38

20 Found: C, 53.59; H, 3.35

m.p. 194-195°C.

6-Bromo-3-methoxy-1-oxo-1H-2-benzopyran-4-carboxylic Acid Methyl Ester

25 ^1H NMR (DMSO- d_6 , 400 MHz): δ 3.81 (s, 3H, $-\text{CO}_2\text{CH}_3$), 4.05 (s, 3H, $-\text{OCH}_3$ -), 7.6 (dd, $J = 8.38$ Hz, 1.77 Hz, 1H, Ar-H), 8.0 (d, $J = 8.39$ Hz, 1H, Ar-H), 8.23 (d, $J = 1.95$ Hz, 1H, Ar-H)

IR (KBr, cm^{-1}): 1740 (CO), 1680 (CO)

MS (m/e): 312 (17 M^+), 284 (45, $\text{M}^+ - \text{CO}$)

Anal. Calcd.: C, 46.03; H, 2.90

30 Found: C, 46.12; H, 2.62

m.p. 200-201°C.

- 16 -

Step c) 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquino-linecarboxylic Acid Methyl Ester

To a solution of 3-methoxy-1-oxo-1H-2-benzopyran-4-carboxylic acid methyl ester (5.0 g, 21.37 mmol) in DMF (100 mL) were added 4-bromo-2-fluorobenzylamine (4.36 g, 21.37 mmol) and Et₃N (5.96 mL, 42.74 mmol). The mixture was stirred at 80°C for 30 minutes, poured into H₂O (1500 mL), acidified with HCl (2N) and extracted with EtOAc. The organic extracts were dried over MgSO₄. Evaporation and crystallization from acetone/hexane (after cooling to -20°C) gave a white solid (7.6 g, 87.7 %, m.p. 149-150°C).

¹H NMR (DMSO-d₆, 400 MHz): δ [3.67 (s), 4.0 (s), 3H, -CO₂Me, tautomeric], [5.06 (q), J = 15.4 Hz, 5.30 (s), 2H, -NCH₂-, tautomeric], 5.4 (s), 1H, CH-CO₂Me, tautomeric], 7.07-8.43 (m, 7H, Ar-H, tautomeric)

IR (KBr, cm⁻¹): 1670 (C=O), 1605 (CO)

MS (+ FAB): 406 (80, M⁺⁺ H), 374 (40, M⁺ -OCH₃)

Anal. Calcd.: C, 53.22; H, 3.23; N, 3.45

Found: C, 53.19; H, 2.98; N, 3.40.

The following compounds were prepared in substantially the same manner as that of Example 1, Step c):

2-[(4-Bromo-2-fluorophenyl)methyl]-6-fluoro-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinolinecarboxylic Acid Methyl Ester

¹H NMR (DMSO-d₆, 400 MHz): δ 3.98 (s, 3H, -CO₂CH₃), 5.27 (s, 2H, -NCH₂-), 7.08 (t, J = 7.95 Hz, 2H, Ar-H), 7.2 (m, 1H, Ar-H), 7.34 (m, 2H, Ar-H, -OH), 7.54 (m, 1H, Ar-H), 8.1-8.26 (m, 2H, Ar-H)

IR (KBr, cm⁻¹): 1680 (CO), 1660 (CO), 1610 (CO)

MS (m/e): 423 (M⁺), 391 (M⁺-CH₃OH)

Anal. Calcd.: C, 50.97; H, 2.85; N, 3.30

Found: C, 50.86; H, 2.86; N, 3.33

m.p. 157-158°C.

- 17 -

6-Chloro-1,2,3,4-tetrahydro-2-methyl-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester

^1H NMR $[(\text{DMSO}-d_6, 200 \text{ MHz})]$: δ [3.23 (s), 3.44 (s), tautomeric, 3H, $-\text{NCH}_3$], [3.71 (s), 4.03 (s), tautomeric, 3H, $-\text{CO}_2\text{CH}_3$], 7.3-8.4 (tautomeric, Ar-H, -OH, 4H)

5 IR (KBr, cm^{-1}): 3440 (OH), 1680 (CO), 1600 (CO)

MS (m/e): 267 (M^+), 235 ($\text{M}^+ - \text{OMe}$)

Anal. Calcd.: C, 53.85; H, 3.77; N, 5.23

Found: C, 53.66; H, 3.63; N, 5.14

m.p. 166-167°C.

10 **6-Bromo-1,2,3,4-tetrahydro-2-methyl-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester**

^1H NMR ($\text{DMSO}-d_6, 400 \text{ MHz}$): δ [3.2 (s), 3.42 (s), 3H, tautomeric, $\text{N}-\text{CH}_3$], [3.7 (s), 4.01 (s), 3H, tautomeric, $-\text{CO}_2\text{CH}_3$], [5.33 (s), 1H, tautomeric, Ar-CH-], [7.5 (dd), 7.8 (dd), tautomeric, 1H, Ar-H], [8.0 (d), 8.08 (d), tautomeric, 1H, Ar-H], [8.51 (d), 7.63 (d), tautomeric, 1H, Ar-H]

IR (KBr, cm^{-1}): 1665 (CO), 605 (CO)

MS (m/e): 311 (M^+)

Anal. Calcd.: C, 46.18; H, 3.23; N, 4.49

Found: C, 45.83; H, 2.77; N, 4.38

20 m.p. 190-191°C.

Step d) 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic Acid 1,1-Dimethylethyl Ester

25 To a suspension of 2-[(4-bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinolinecarboxylic acid methyl ester (4.79 g, 11.58 mmol), K_2CO_3 (3.19 g, 23.16 mmol) in DMF (100 mL) was added tert-butyl bromoacetate (2.81 mL, 17.37 mmol). After stirring at 75°C for 1 hour, the mixture was poured into H_2O , extracted with EtOAc and dried over MgSO_4 . Evaporation and purification by flash chromatography (hexane/EtOAc 4/1) gave a clear oil (5.69 g, 94.5%).

30 ^1H NMR ($\text{DMSO}-d_6, 400 \text{ MHz}$): δ 1.04 [s, 9H, $-\text{C}(\text{CH}_3)_3$], 3.53 s, 3H, $-\text{CO}_2\text{CH}_3$, 3.60 [dd, $J = 17.7 \text{ Hz}$, 2H, $-\text{CH}_2\text{CO}_2(\text{CH}_3)_3$], 5.14 (s, 2H, NCH_2-), 7.17 (t, $J =$

- 18 -

8.25 Hz, 1H, Ar-H), 7.36 (dd, J = 8.36 Hz, 1.75 Hz, 1H, Ar-H), 7.6 (m, 3H, Ar-H), 7.77 (dt, J = 7.2 Hz, 1.27 Hz, 1H, Ar-H), 8.19 (dd, J = 8.25 Hz, 1.54 Hz, 1H, Ar-H)

IR (CHCl₃, cm⁻¹): 1720 (CO), 1675 (CO)

5 MS (m/e): 520 (M + H)⁺, 464 [M⁺-C(CH₃)₃].

The following compounds were prepared in substantially the same manner as that of Example 1, Step d):

2-[(4-Bromo-2-fluorophenyl)methyl]-6-fluoro-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic Acid 1,1-

10 **Dimethylethyl Ester**

¹H NMR (DMSO-d₆, 200 MHz): δ 1.10 (s, 9H, -CMe₃), 3.55 (s, 3H, -CO₂CH₃), 3.62 (d, J = 17.5 Hz, 1H, -CH₂CO₂CMe₃), 3.75 (d, J = 17.5 Hz, 1H, -CH₂CO₂CMe₃), 5.15 (s, 2H, -NCH₂-), 7.15 (t, J = 8.2 Hz, 1H, Ar-H), 7.35 (d, J = 8.2 Hz, 1H, Ar-H), 7.45-7.70 (m, 3H, Ar-H), 8.38 (dd, J = 8.16 Hz, 5.70 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 1750 (CO), 1720 (CO), 1675 (CO)

MS (m/e): 538 (M + H)⁺, 481 (M⁺ + H-CMe₃)

Anal. Calcd.: C, 53.55; H, 4.12; N, 2.60

Found: C, 53.49; H, 4.00; N, 2.63.

20 **6-Chloro-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-2-methyl-1,3-dioxo-4-isoquinolineacetic Acid 1,1-Dimethylethyl Ester**

¹H NMR (DMSO-d₆, 200 MHz): δ 1.06 (s, 9H, -CO₂CMe₃), 3.3 (s, 3H, -NCH₃), 3.6 (s, 3H, -CO₂CH₃), 3.67 (q, J = 17.5 Hz, 2H, -CH₂CO₂CMe₃), 7.68 (dd, J = 9.0 Hz, 1.6 Hz, 1H, Ar-H), 7.77 (d, J = 2.0 Hz, 1H, Ar-H), 8.21 (d, J = 8.2 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 1740 (CO), 1720 (CO), 1680 (CO)

MS (m/e): 381 (M⁺)

Anal. Calcd.: C, 56.82; H, 5.28; N, 3.67

Found: C, 57.00; H, 5.41; N, 3.66

30 m.p. 135-136°C.

- 19 -

6-Bromo-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-2-methyl-1,3-dioxo-4-isoquinolineacetic Acid 1,1-Dimethylethyl Ester

¹H NMR (DMSO-d₆, 200 MHz): δ 1.05 [s, 9H, -C(CH₃)₃], 3.28 (s, 3H, -NCH₃), 3.59 (s, 3H, -CO₂CH₃), 3.58 (d, J = 17.03 Hz, 1H, -CH₂CO₂-), 3.67 (d, J = 17.03 Hz, 1H, -CH₂CO₂-), 7.81 (dd, J = 8.4 Hz, 1.85 Hz, 1H, Ar-H), 7.88 (d, J = 1.81 Hz, 1H, Ar-H), 8.08 (d, J = 8.4 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 1740 (CO), 1710 (CO), 1670 (CO)

MS (m/e): 425 (M⁺), 370 (M⁺ - C₄H₇), 352 (M⁺ - C₄H₉O)

Anal. Calcd.: AC, 50.72; H, 4.73; N, 3.29

Found: C, 50.47; H, 4.68; N, 3.12

m.p. 152-153°C.

Step e) 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic Acid

A mixture of 2-[(4-bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid 1,1-dimethylethyl ester (5.19 g, 9.81 mmol), CH₂Cl₂ (100 mL) and CF₃CO₂H (20 mL) was stirred at room temperature for 5 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography on acid washed silica gel (5% H₃PO₄ in MeOH), to give a white solid (4.12 g, 90.5%, m.p. 139-140°C).

¹H NMR (DMSO-d₆, 400 MHz): δ 3.54 (s, 3H, CO₂CH₃), 3.64 (q, J = 17.67 Hz, 2H, CH₂CO₂H), 5.12 (q, J = 15.34 Hz, 2H, -NCH₂-), 7.14 (t, J = 8.22 Hz, 1H, Ar-H), 7.3 (d, J = 8.3 Hz, 1H, Ar-H), 7.5-7.6 (m, 3H, Ar-H), 7.76 (d, J = 7.4 Hz, 1H, Ar-H), 8.16 (d, J = 7.8 Hz, 1H, Ar-H), 12.35 (s, 1H, -CO₂H)

IR (KBr, cm⁻¹): 3280 (OH), 3200-2700 (CO₂H), 1750 (CO), 1720 (CO), 1675 (CO)

MS (m/e): 463 (M⁺), 445 (M⁺ - H, -OH)

Anal. Calcd.: C, 51.28; H, 3.30; N, 2.99

Found: C, 51.26; H, 3.48; N, 2.95.

- 20 -

The following compound was obtained in substantially the same manner as that of Example 1, Step e):

2-[(4-Bromo-2-fluorophenyl)methyl]-6-fluoro-1,2,3,4-tetrahydro-4-(methoxy- carbonyl)-1,3-dioxo-4-isoquinolineacetic Acid

5 ^1H NMR (DMSO- d_6 , 400 MHz): δ 3.56 (s, 3H, $-\text{CO}_2\text{CH}_3$), 3.6(d, J = 17.9 Hz, 1H, $-\text{CH}_2\text{CO}_2\text{H}$), 3.8 (d, J = 17.9 Hz, 1H, $-\text{CH}_2\text{CO}_2\text{H}$), 5.1 (dd, J = 15.5 Hz, 2H, $-\text{NCH}_2-$), 7.12 (s, J = 8.23 Hz, 1H, Ar-H), 7.31 (dd, J = 8.28 Hz, 1.68 Hz, 1H, Ar-H), 7.45 (dt, J = 8.56 Hz, 2.5 Hz, 1H, Ar-H), 7.54 (dd, J = 9.77 Hz, 1.89 Hz, 1H, Ar-H), 7.64 (dd, J = 9.61 Hz, 2.46 Hz, 1H, Ar-H), 8.23 (dd, J = 8.79 Hz, 5.81 Hz, 1H, Ar-H), 12.67 (br s, 1H, $-\text{CO}_2\text{H}$)

IR (KBr, cm^{-1}): 3400-2700 (CO_2H), 1745 (CO), 1710 (CO), 1670 (CO)

MS (m/e): 481 (M^+), 405 ($\text{M}^+ - \text{CO}_2$, $-\text{CH}_3\text{OH}$)

Anal. Calcd.: C, 49.81; H, 2.93; N, 2.90

Found: C, 49.94; H, 3.03; N, 2.84

15 m.p. 132-133.5°C.

6-Chloro-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-2-methyl-1,3-dioxo-4-isoquinolineacetic Acid

^1H NMR (DMSO- d_6 , 200 MHz): δ 3.27 (s, 3H, $-\text{CH}_3$), 3.59 (s, 3H, $-\text{CO}_2\text{CH}_3$), 3.64 (q, J = 17.5 Hz, 2H, $-\text{CH}_2\text{CO}_2\text{H}$), 7.65 (dd, J = 8.6 Hz, 2.0 Hz, 1H, Ar-H), 7.78 (d, J = 2.0 Hz, 1H, Ar-H), 8.18 (d, J = 8.0 Hz, 1H, Ar-H)

IR (KBr, cm^{-1}): 3440 (OH), 3200-2700 (CO_2H), 1750 (CO), 1710 (CO), 1675 (CO)

MS (m/e): 325 (M^+)

Anal. Calcd.: C, 51.63; H, 3.71; N, 4.30

Found: C, 51.73; H, 2.70; N, 4.28

25 m.p. 195-196°C.

6-Bromo-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-2-methyl-1,3-dioxo-4-isoquinolineacetic Acid

^1H NMR (DMSO- d_6 , 200 MHz): δ 3.26 (s, 3H, N- CH_3), 3.53 (d, J = 17.2 Hz, 1H, $-\text{CH}_2\text{H}$), 3.58 (s, 3H, $-\text{CO}_2\text{CH}_3$), 3.74 (d, J = 17.2 Hz, 1H, $-\text{CH}_2\text{CO}_2\text{H}$), 7.77 (dd,

- 21 -

$J = 8.2$ Hz, 2.2 Hz, $1H$, Ar-H), 7.87 (d, $J = 2.2$ Hz, $1H$, Ar-H), 8.0 (d, $J = 8.2$ Hz, $1H$, Ar-H), 12.64 (s, $1H$, -CO₂H)

IR (KBr, cm⁻¹): $3450-2600$ (CO₂H), 1735 (CO), 1700 (CO), 1660 (CO)

MS (m/e): 369 (M⁺), 324 (M⁺-CO₂H)

5 Anal. Calcd.: C, 45.43; H, 3.27; N, 3.78

 Found: C, 45.04; H, 3.16; N, 3.62

m.p. $194-195^{\circ}C$.

Step f) 1'-Amino-2-[(4-bromo-2-fluorophenyl)methyl]spiro[isoquinoline-4(1H),3'-pyrrolidine]-
10 **1,2',3,5'(2H)-tetrone**

 To a solution of 2-[(4-bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid (2.5 g, 5.39 mmol) in DMF (60 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DCC, 1.34 g, 7.0 mmol) and 1-hydroxybenzotriazole hydrate (HOBT, 1.09 g, 8.08
15 mmol). After stirring for 2 hours, anhydrous hydrazine (0.22 mL, 7.0 mmol) was added dropwise, followed by Et₃N (1.5 mL, 10.77 mmol) addition. The mixture was stirred for 30 minutes, poured into H₂O, neutralized with HCl (2N) and extracted with EtOAc. The organic extracts were dried over MgSO₄. Evaporation and purification by flash chromatography (hexane/EtOAc 1:1) and subsequent crystallization from
20 ether/hexane (after cooling to $-20^{\circ}C$) gave a white solid (1.68 g, 70.0%, m.p. $95-97^{\circ}C$).

1H NMR (DMSO-d₆, 400 MHz): δ 3.33 (d, $J = 18.2$ Hz, $1H$, -HCHCO-), 3.51 (d, $J = 18.2$ Hz, $1H$, -HCHCO-), 5.07 (s, $2H$, -NCH₂-), 5.23 (s, $2H$, -NH₂), 7.17 (t, $J = 8.3$ Hz, $1H$, Ar-H), 7.33 (dd, $J = 8.3$ Hz, 1.7 Hz, $1H$, Ar-H), 7.54 (m, $2H$, Ar-H),
25 7.63 (t, $J = 8.51$ Hz, $1H$, Ar-H), 7.79 (dt, $J = 8.7$ Hz, 1.25 Hz, $1H$, Ar-H), 8.18 (dd, $J = 7.7$ Hz, 1.25 Hz, $1H$, Ar-H)

IR (KBr cm⁻¹): 3340 (NH), 1720 (C=O), 1670 (C=O)

MS (m/e): $445(4, M^+)$

Anal. Calcd.: C, 51.14; H, 2.94; N, 9.42

30 Found: C, 51.04; H, 2.94; N, 9.30.

- 22 -

The following compound was prepared in substantially the same manner as that of Example 1, Step f)

1'-Amino-2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone

- 5 ^1H NMR (DMSO- d_6 , 400 MHz): δ 3.42 (q, $J = 18.2$ Hz, 2H, $-\text{CH}_2\text{CO}-$), 5.05 (s, 2H, $-\text{NCH}_2-$), 5.18 (s, 2H, $-\text{NH}_2$), 7.15 (t, $J = 8.3$ Hz, 1H, Ar-H), 7.33 (dd, $J = 8.1$ Hz, 1.66 Hz, 1H, Ar-H), 7.49 (dt, $J = 8.5$ Hz, 2.29 Hz, 1H, Ar-H), 7.55 (dd, $J = 9.96$ Hz, 1.87 Hz, 1H, Ar-H), 7.6 (dd, $J = 9.75$ Hz, 2.49 Hz, 1H, Ar-H), 8.24 (dd, $J = 8.9$ Hz, 5.8 Hz, 1H, Ar-H)
- 10 IR (KBr, cm^{-1}): 3350 (NH), 3280 (NH), 1730 (C=O), 1710 (C=O), 1670 (C=O)
MS (m/e): 463 (94 M^+)

Anal. Calcd.: C, 49.16; H, 2.61; N, 9.05

Found: C, 49.19; H, 2.66; N, 8.96

m.p. 232-234°C.

15

EXAMPLE 2

N-[2-[(4-Bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro-[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]-iminodicarbonic Acid Dimethyl Ester

- 20 To a cold (0°C) solution of 1'-amino-2-[(4-bromo-2-fluorophenyl)methyl]spiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone (2.0 g, 4.48 mmol) in THF (50 mL) was added Et_3N (3.12 mL, 22.4 mmol) followed by dropwise addition of methyl chloroformate (1.04 mL, 13.44 mmol). After stirring for 30 minutes, the mixture was poured into H_2O , acidified with HCl (2N) and extracted with EtOAc. The organic extracts were dried over MgSO_4 . Evaporation and purification by flash
- 25 chromatography on silica gel (hexane/EtOAc 2:1) gave a white solid (2.1 g, 83.3%, m.p. 214-216°C).

- 23 -

¹H NMR (DMSO-d₆, 400 MHz): δ 3.74 (s, 3H, -CO₂CH₃), 3.76 (d, J = 18.9 Hz, 1H, -HCHCO-), 3.81 (d, J = 18.9 Hz, 1H, -HCHCO-), 3.83 (s, 3H, -CO₂CH₃), 5.1 (s, 2H, -NCH₂-), 7.18 (t, J = 8.1 Hz, 1H, Ar-H), 7.34 (dd, J = 8.3 Hz, 1.87 Hz, 1H, Ar-H), 7.56 (m, 2H, Ar-H), 7.68 (t, J = 7.47 Hz, 1H, Ar-H), 7.86 (dt, J = 7.68 Hz, 1.45 Hz, 1H, Ar-H), 8.21 (dd, J = 7.88 Hz, 1.25 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 1810 (C=O), 1745 (C=O), 1670 (C=O)

MS (m/e): 561 (50, M⁺)

Anal. Calcd.: C, 49.13; H, 3.05; N, 7.47

Found: C, 49.33; H, 3.22; N, 7.26.

10

EXAMPLE 3

N-[2-[(4-Bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro-[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]acetamide

A mixture of 1'-amino-2-[(4-bromo-2-fluorophenyl)methyl]spiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone (2.0 g, 4.48 mmol) and acetic anhydride (20 mL) was stirred at 70°C for 30 minutes. The volatiles were removed in vacuo and the residue was purified by flash chromatography on silica gel (hexane/EtOAc 1:1) to give a white solid (1.91 g, 87.3%, m.p. 219-221°C).

¹H NMR (DMSO-d₆, 400 MHz): δ 1.98 (s, 3H, -COCH₃), 3.5 (d, J = 18.9 Hz, 1H, -HCHCO-), 3.7 (d, J = 18.9 Hz, 1H, -HCHCO-), 5.09 (dd, J = 16.2 Hz, 2H, -CH₂-N), 7.17 (t, J = 8.3 Hz, 1H, Ar-H), 7.35 (d, J = 7.9 Hz, 1H, Ar-H), 7.56 (m, 2H, Ar-H), 7.65 (t, J = 7.68 Hz, 1H, Ar-H), 7.84 (dt, J = 7.68 Hz, 1.25 Hz, 1H, Ar-H), 8.17 (dd, J = 7.88 Hz, 1.25 Hz, 1H, Ar-H), 10.95 (s, 1H, -NHCOCH₃)

IR (KBr, cm⁻¹): 3240 (NH), 1740 (C=O), 1700 (C=O), 1660 (C=O)

MS (m/e): 487 (54 M⁺), 387 (100, M⁺-CONNHCOCH₃)

Anal. Calcd.: C, 51.66; H, 3.10; N, 8.61

Found: C, 51.46; H, 3.12; N, 8.54.

- 24 -

EXAMPLE 4

**N-[2-[(4-Bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-
tetraoxospiro- [isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]-1,1,1-
trifluoromethanesulfonamide**

- 5 To a cold (0°C) solution of 1'-amino-2-[(4-bromo-2-fluorophenyl)methyl]spiro-
[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone (2.0 g, 4.48 mmol) in
anhydrous CH₂Cl₂ was added Et₃N (3.12 mL, 22.4 mmol), followed by dropwise
addition of (CF₃SO₂)₂O (2.26 mL, 13.44 mmol). After stirring for 30 minutes the
mixture was poured into H₂O, acidified with HCl (2N) and extracted with EtOAc.
10 Evaporation and purification by flash chromatography, on acid washed silica gel
(hexane/EtOAc 1:1) gave a yellow solid (1.1 g, 42.5%, m.p. 98-100°C).

¹H NMR (DMSO-d₆, 400 MHz): δ 3.29 (d, J = 18.5 Hz, 1H, -HCHCO-), 3.5 (d, J =
18.5 Hz, 1H, -HCHCO-), 5.07 (s, 2H, -NCH₂-), 7.18 (t, J = 8.1 Hz, 1H, Ar-H),
7.32 (dd, J = 8.3 Hz, 1.87 Hz, 1H, Ar-H), 7.38 (d, J = 7.88 Hz, 1H, Ar-H), 7.53 (dd,
15 J = 9.96 Hz, 2.07 Hz, 1H, Ar-H), 7.62 (t, J = 8.5 Hz, 1H, Ar-H), 7.78 (dt, J = 7.9
Hz, 1.25 Hz, 1H, Ar-H), 8.15 (dd, J = 7.9 Hz, 1.25 Hz, 1H, Ar-H)

IR (KBr, cm⁻¹): 3400 (NH), 1750 (C=O), 1670 (C=O)

MS (m/e): 577 (94, M⁺), 387 (60, M⁺ -CONH₂SO₂CF₃)

Anal. Calcd.: C, 41.54; H, 2.09; N, 7.27


20 Found: C, 41.20; H, 2.03; N, 7.19.

- 25 -

CLAIMS

We claim:

1. The compounds of structural formula (I)



5 wherein:


R¹ and R² are independently hydrogen, alkyl containing 1 to 6 carbon atoms, halogen, lower alkoxy containing 1 to 6 carbon atoms, trifluoromethyl, nitro, aryl or aryl (lower alkyl) oxy wherein aryl contains 6 to 10 carbon atoms and lower alkyl contains 1 to 6 carbon atoms;

10 R³ is lower alkyl containing 1 to 6 carbon atoms, aryl, aryl (lower alkyl) or dihalogen substituted aryl (lower alkyl) wherein aryl contains 6 to 10 carbon atoms and lower alkyl contains 1 to 6 carbon atoms;

15 R⁴ and R⁵ are independently hydrogen, alkyl containing 1 to 6 carbon atoms, aryl or aryl (lower alkyl) wherein aryl contains 6 to 10 carbon atoms and lower alkyl contains 1 to 6 carbon atoms, acyl, carboalkoxy, alkylsulfoxy, arylsulfoxy, alkylsulfonyl, or arylsulfonyl and the pharmaceutically acceptable salts thereof when R⁴ and R⁵ are hydrogen, alkyl or aryl.

- 26 -

2. The compounds according to claim 1 of structural formula (II)




wherein R¹ and R² are hydrogen or halogen, R³ is a dihalogen substituted benzyl, R⁴ and R⁵ are hydrogen, acyl, carboalkoxy or trifluoromethylsulfonyl.

- 5 3. The compound according to claim 2 1'-amino-2-[(4-bromo-2-fluorophenyl)-methyl]spiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2,3,5'(2H)-tetrone.
4. The compound according to claim 2 1'-amino-2-[(4-bromo-2-fluorophenyl)-methyl]-6-fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2,3,5'(2H)-tetrone.
- 10 5. The compound according to claim 2 N-[2-[(4-bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]iminodicarbonic acid dimethyl ester.
6. The compound according to claim 2 N-[2-[(4-bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]-acetamide.
- 15 7. The compound according to claim 2 N-[2-[(4-bromo-2-fluorophenyl)methyl]-2,3-dihydro-1,2',3,5'-tetraoxospiro[isoquinoline-4(1H),3'-pyrrolidin]-1'-yl]-1,1,1-trifluoromethansulfonamide.

INTERNATIONAL SEARCH REPORT

PCT/US 91/07473

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07D471/10; //A61K31/435, (C07D471/10, 221:00, 209:00)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 365 324 (AMERICAN HOME PRODUCTS) 25 Apr11 1990 & US-A-4927831, cited by the applicant see claim 1 ---	1
<p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 05 FEBRUARY 1992		Date of Mailing of this International Search Report 24. 02. 92
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer ALFARO FAUS I. 

US 9107473
SA 53282

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82